Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 145 entries
Sorted by: Best Match Show Resources per page
Preference of diagnostic tools, medications, and devices for asthma management: A survey of doctors in Algeria.

Perspectives in clinical research

Gogtay J, Laouar L, Gaur V.
PMID: 31008072
Perspect Clin Res. 2019 Apr-Jun;10(2):67-72. doi: 10.4103/picr.PICR_63_18.

AIM: This study aimed to evaluate the doctors' perspectives in using tools for diagnosis, prescribing medications, and devices for the treatment of asthma in Algeria.METHODS: Data were collected from randomly selected physicians, pediatricians, allergists, and pulmonologists through a questionnaire-based...

Cite
Gogtay J, Laouar L, Gaur V. Preference of diagnostic tools, medications, and devices for asthma management: A survey of doctors in Algeria. Perspect Clin Res. 2019;10(2):67-72doi: 10.4103/picr.PICR_63_18.
Gogtay, J., Laouar, L., & Gaur, V. (2019). Preference of diagnostic tools, medications, and devices for asthma management: A survey of doctors in Algeria. Perspectives in clinical research, 10(2), 67-72. https://doi.org/10.4103/picr.PICR_63_18
Gogtay, Jaideep, et al. "Preference of diagnostic tools, medications, and devices for asthma management: A survey of doctors in Algeria." Perspectives in clinical research vol. 10,2 (2019): 67-72. doi: https://doi.org/10.4103/picr.PICR_63_18
Gogtay J, Laouar L, Gaur V. Preference of diagnostic tools, medications, and devices for asthma management: A survey of doctors in Algeria. Perspect Clin Res. 2019 Apr-Jun;10(2):67-72. doi: 10.4103/picr.PICR_63_18. PMID: 31008072; PMCID: PMC6463497.
Copy Download .nbib Format: NLM
Beclomethasone dipropionate and sodium cromoglycate protect against airway hyperresponsiveness in a human ex vivo model of cow's milk aspiration.

Current research in pharmacology and drug discovery

Ritondo BL, Rogliani P, Facciolo F, Falco S, Vocale A, Calzetta L.
PMID: 34909646
Curr Res Pharmacol Drug Discov. 2020 Dec 08;2:100010. doi: 10.1016/j.crphar.2020.100010. eCollection 2021.

BACKGROUND: Recurrent cow's milk (CM) aspiration is often associated with gastroesophageal reflux in infants and toddlers and it seems to be implicated in the etiology of different inflammatory lung disorders. This study aimed to investigate ex vivo the impact...

Cite
Ritondo BL, Rogliani P, Facciolo F, et al. Beclomethasone dipropionate and sodium cromoglycate protect against airway hyperresponsiveness in a human ex vivo model of cow's milk aspiration. Curr Res Pharmacol Drug Discov. 2020;2:100010doi: 10.1016/j.crphar.2020.100010.
Ritondo, B. L., Rogliani, P., Facciolo, F., Falco, S., Vocale, A., & Calzetta, L. (2021). Beclomethasone dipropionate and sodium cromoglycate protect against airway hyperresponsiveness in a human ex vivo model of cow's milk aspiration. Current research in pharmacology and drug discovery, 2100010. https://doi.org/10.1016/j.crphar.2020.100010
Ritondo, Beatrice Ludovica, et al. "Beclomethasone dipropionate and sodium cromoglycate protect against airway hyperresponsiveness in a human ex vivo model of cow's milk aspiration." Current research in pharmacology and drug discovery vol. 2 (2021): 100010. doi: https://doi.org/10.1016/j.crphar.2020.100010
Ritondo BL, Rogliani P, Facciolo F, Falco S, Vocale A, Calzetta L. Beclomethasone dipropionate and sodium cromoglycate protect against airway hyperresponsiveness in a human ex vivo model of cow's milk aspiration. Curr Res Pharmacol Drug Discov. 2020 Dec 08;2:100010. doi: 10.1016/j.crphar.2020.100010. eCollection 2021. PMID: 34909646; PMCID: PMC8663930.
Copy Download .nbib Format: NLM
[Risk of diabetes mellitus during regular long-term inhaled glucocorticoid treatment in COPD patients: narrative review of the literature.].

Recenti progressi in medicina

Arpinelli F, Nucera F, Ruggeri P, Lo Bello F, Magnoni MS, Caramori G.
PMID: 34647537
Recenti Prog Med. 2021 Oct;112(10):668-677. doi: 10.1701/3679.36658.

Glucocorticoids are anti-inflammatory drugs used in combination with inhaled bronchodilators, such as β2-agonists and antimuscarinics, for the treatment of stable chronic obstructive pulmonary disease (COPD), to improve respiratory symptoms, such as exertional dyspnoea, and to decrease the risk of...

Cite
Arpinelli F, Nucera F, Ruggeri P, et al. Rischio di diabete mellito durante il trattamento regolare a lungo termine con glucocorticoidi per via inalatoria nei pazienti con BPCO: revisione narrativa della letteratura. [Risk of diabetes mellitus during regular long-term inhaled glucocorticoid treatment in COPD patients: narrative review of the literature.]. Recenti Prog Med. 2021;112(10):668-677doi: 10.1701/3679.36658.
Arpinelli, F., Nucera, F., Ruggeri, P., Lo Bello, F., Magnoni, M. S., & Caramori, G. (2021). Rischio di diabete mellito durante il trattamento regolare a lungo termine con glucocorticoidi per via inalatoria nei pazienti con BPCO: revisione narrativa della letteratura. [Risk of diabetes mellitus during regular long-term inhaled glucocorticoid treatment in COPD patients: narrative review of the literature.]. Recenti progressi in medicina, 112(10), 668-677. https://doi.org/10.1701/3679.36658
Arpinelli, Fabio, et al. "Rischio di diabete mellito durante il trattamento regolare a lungo termine con glucocorticoidi per via inalatoria nei pazienti con BPCO: revisione narrativa della letteratura." [Risk of diabetes mellitus during regular long-term inhaled glucocorticoid treatment in COPD patients: narrative review of the literature.]. Recenti progressi in medicina vol. 112,10 (2021): 668-677. doi: https://doi.org/10.1701/3679.36658
Arpinelli F, Nucera F, Ruggeri P, Lo Bello F, Magnoni MS, Caramori G. Rischio di diabete mellito durante il trattamento regolare a lungo termine con glucocorticoidi per via inalatoria nei pazienti con BPCO: revisione narrativa della letteratura. [Risk of diabetes mellitus during regular long-term inhaled glucocorticoid treatment in COPD patients: narrative review of the literature.]. Recenti Prog Med. 2021 Oct;112(10):668-677. doi: 10.1701/3679.36658. Italian. PMID: 34647537.
Copy Download .nbib Format: NLM
Beclomethasone dipropionate and sodium cromoglycate protect against airway hyperresponsiveness in a human ex vivo model of cow's milk aspiration.

Current research in pharmacology and drug discovery

Ritondo BL, Rogliani P, Facciolo F, Falco S, Vocale A, Calzetta L.
PMID: 34909646
Curr Res Pharmacol Drug Discov. 2020 Dec 08;2:100010. doi: 10.1016/j.crphar.2020.100010. eCollection 2021.

BACKGROUND: Recurrent cow's milk (CM) aspiration is often associated with gastroesophageal reflux in infants and toddlers and it seems to be implicated in the etiology of different inflammatory lung disorders. This study aimed to investigate ex vivo the impact...

Cite
Ritondo BL, Rogliani P, Facciolo F, et al. Beclomethasone dipropionate and sodium cromoglycate protect against airway hyperresponsiveness in a human ex vivo model of cow's milk aspiration. Curr Res Pharmacol Drug Discov. 2020;2:100010doi: 10.1016/j.crphar.2020.100010.
Ritondo, B. L., Rogliani, P., Facciolo, F., Falco, S., Vocale, A., & Calzetta, L. (2021). Beclomethasone dipropionate and sodium cromoglycate protect against airway hyperresponsiveness in a human ex vivo model of cow's milk aspiration. Current research in pharmacology and drug discovery, 2100010. https://doi.org/10.1016/j.crphar.2020.100010
Ritondo, Beatrice Ludovica, et al. "Beclomethasone dipropionate and sodium cromoglycate protect against airway hyperresponsiveness in a human ex vivo model of cow's milk aspiration." Current research in pharmacology and drug discovery vol. 2 (2021): 100010. doi: https://doi.org/10.1016/j.crphar.2020.100010
Ritondo BL, Rogliani P, Facciolo F, Falco S, Vocale A, Calzetta L. Beclomethasone dipropionate and sodium cromoglycate protect against airway hyperresponsiveness in a human ex vivo model of cow's milk aspiration. Curr Res Pharmacol Drug Discov. 2020 Dec 08;2:100010. doi: 10.1016/j.crphar.2020.100010. eCollection 2021. PMID: 34909646; PMCID: PMC8663930.
Copy Download .nbib Format: NLM
Bronchial Thermoplasty in Severe Asthmatics At 5 Years: The PAS2 Study.

Chest

Chupp G, Kline JN, Khatri SB, McEvoy C, Silvestri GA, Shifren A, Castro M, Bansal S, McClelland M, Dransfield M, Trevor J, Kahlstrom N, Simoff M, Wahidi MM, Lamb CR, Ferguson JS, Haas A, Hogarth DK, Tejedor R, Toth J, Hey J, Majid A, LaCamera P, FitzGerald JM, Enfield K, Grubb GM, McMullen EA, Olson JL, Laviolette M.
PMID: 34774528
Chest. 2021 Nov 10; doi: 10.1016/j.chest.2021.10.044. Epub 2021 Nov 10.

BACKGROUND: Bronchial thermoplasty is a device-based treatment for subjects ≥18 years with severe asthma poorly controlled with inhaled corticosteroids and long-acting beta-agonists. The Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty in Severe Persistent Asthma (PAS2) study collected data on...

Cite
Chupp G, Kline JN, Khatri SB, et al. Bronchial Thermoplasty in Severe Asthmatics At 5 Years: The PAS2 Study. Chest. 2021;doi: 10.1016/j.chest.2021.10.044.
Chupp, G., Kline, J. N., Khatri, S. B., McEvoy, C., Silvestri, G. A., Shifren, A., Castro, M., Bansal, S., McClelland, M., Dransfield, M., Trevor, J., Kahlstrom, N., Simoff, M., Wahidi, M. M., Lamb, C. R., Ferguson, J. S., Haas, A., Hogarth, D. K., Tejedor, R., Toth, J., Hey, J., Majid, A., LaCamera, P., FitzGerald, J. M., Enfield, K., Grubb, G. M., McMullen, E. A., Olson, J. L., & Laviolette, M. (2021). Bronchial Thermoplasty in Severe Asthmatics At 5 Years: The PAS2 Study. Chest, . https://doi.org/10.1016/j.chest.2021.10.044
Chupp, Geoffrey, et al. "Bronchial Thermoplasty in Severe Asthmatics At 5 Years: The PAS2 Study." Chest vol. (2021). doi: https://doi.org/10.1016/j.chest.2021.10.044
Chupp G, Kline JN, Khatri SB, McEvoy C, Silvestri GA, Shifren A, Castro M, Bansal S, McClelland M, Dransfield M, Trevor J, Kahlstrom N, Simoff M, Wahidi MM, Lamb CR, Ferguson JS, Haas A, Hogarth DK, Tejedor R, Toth J, Hey J, Majid A, LaCamera P, FitzGerald JM, Enfield K, Grubb GM, McMullen EA, Olson JL, Laviolette M. Bronchial Thermoplasty in Severe Asthmatics At 5 Years: The PAS2 Study. Chest. 2021 Nov 10; doi: 10.1016/j.chest.2021.10.044. Epub 2021 Nov 10. PMID: 34774528.
Copy Download .nbib Format: NLM
Psychometric validation of the experience with allergic rhinitis nasal spray questionnaire.

Patient related outcome measures

Crawford B, Stanford RH, Wong AY, Dalal AA, Bayliss MS.
PMID: 22915973
Patient Relat Outcome Meas. 2011 Jul;2:127-33. doi: 10.2147/PROM.S19371. Epub 2011 Jun 16.

BACKGROUND: Patient experience and preference are critical factors influencing compliance in patients with allergic rhinitis (AR) receiving intranasal corticosteroids. The Experience with Allergic Rhinitis Nasal Spray Questionnaire (EARNS-Q) was developed to measure subject experiences with and preferences for nasal...

Cite
Crawford B, Stanford RH, Wong AY, et al. Psychometric validation of the experience with allergic rhinitis nasal spray questionnaire. Patient Relat Outcome Meas. 2011;2:127-33doi: 10.2147/PROM.S19371.
Crawford, B., Stanford, R. H., Wong, A. Y., Dalal, A. A., & Bayliss, M. S. (2011). Psychometric validation of the experience with allergic rhinitis nasal spray questionnaire. Patient related outcome measures, 2127-33. https://doi.org/10.2147/PROM.S19371
Crawford, Bruce, et al. "Psychometric validation of the experience with allergic rhinitis nasal spray questionnaire." Patient related outcome measures vol. 2 (2011): 127-33. doi: https://doi.org/10.2147/PROM.S19371
Crawford B, Stanford RH, Wong AY, Dalal AA, Bayliss MS. Psychometric validation of the experience with allergic rhinitis nasal spray questionnaire. Patient Relat Outcome Meas. 2011 Jul;2:127-33. doi: 10.2147/PROM.S19371. Epub 2011 Jun 16. PMID: 22915973; PMCID: PMC3417928.
Copy Download .nbib Format: NLM
Glucocorticoid receptor-dependent induction of .

Toxicology reports

Garland MA, Sengupta S, Mathew LK, Truong L, de Jong E, Piersma AH, La Du J, Tanguay RL.
PMID: 31249786
Toxicol Rep. 2019 May 29;6:529-537. doi: 10.1016/j.toxrep.2019.05.013. eCollection 2019.

We previously used a chemical genetics approach with the larval zebrafish to identify small molecule inhibitors of tissue regeneration. This led to the discovery that glucocorticoids (GC) block early stages of tissue regeneration by the inappropriate activation of the...

Cite
Garland MA, Sengupta S, Mathew LK, et al. Glucocorticoid receptor-dependent induction of . Toxicol Rep. 2019;6:529-537doi: 10.1016/j.toxrep.2019.05.013.
Garland, M. A., Sengupta, S., Mathew, L. K., Truong, L., de Jong, E., Piersma, A. H., La Du, J., & Tanguay, R. L. (2019). Glucocorticoid receptor-dependent induction of . Toxicology reports, 6529-537. https://doi.org/10.1016/j.toxrep.2019.05.013
Garland, Michael A, et al. "Glucocorticoid receptor-dependent induction of ." Toxicology reports vol. 6 (2019): 529-537. doi: https://doi.org/10.1016/j.toxrep.2019.05.013
Garland MA, Sengupta S, Mathew LK, Truong L, de Jong E, Piersma AH, La Du J, Tanguay RL. Glucocorticoid receptor-dependent induction of . Toxicol Rep. 2019 May 29;6:529-537. doi: 10.1016/j.toxrep.2019.05.013. eCollection 2019. PMID: 31249786; PMCID: PMC6584771.
Copy Download .nbib Format: NLM
The effects of long-acting β2-agonists plus inhaled corticosteroids for early reversibility in patients with airway obstruction.

Journal of thoracic disease

Ozkaya S, Dirican A, Tuna T.
PMID: 23991303
J Thorac Dis. 2013 Aug;5(4):461-5. doi: 10.3978/j.issn.2072-1439.2013.08.22.

BACKGROUND: Salbutamol, as a short-acting β2-agonist, was popularly used in the past for detection of reversibility in patients with airway obstruction when it was the only drug available in the treatment of airway obstruction. Today, the combination of long-acting...

Cite
Ozkaya S, Dirican A, Tuna T. The effects of long-acting β2-agonists plus inhaled corticosteroids for early reversibility in patients with airway obstruction. J Thorac Dis. 2013;5(4):461-5doi: 10.3978/j.issn.2072-1439.2013.08.22.
Ozkaya, S., Dirican, A., & Tuna, T. (2013). The effects of long-acting β2-agonists plus inhaled corticosteroids for early reversibility in patients with airway obstruction. Journal of thoracic disease, 5(4), 461-5. https://doi.org/10.3978/j.issn.2072-1439.2013.08.22
Ozkaya, Sevket, et al. "The effects of long-acting β2-agonists plus inhaled corticosteroids for early reversibility in patients with airway obstruction." Journal of thoracic disease vol. 5,4 (2013): 461-5. doi: https://doi.org/10.3978/j.issn.2072-1439.2013.08.22
Ozkaya S, Dirican A, Tuna T. The effects of long-acting β2-agonists plus inhaled corticosteroids for early reversibility in patients with airway obstruction. J Thorac Dis. 2013 Aug;5(4):461-5. doi: 10.3978/j.issn.2072-1439.2013.08.22. PMID: 23991303; PMCID: PMC3755673.
Copy Download .nbib Format: NLM
Regulation of CYP3A genes by glucocorticoids in human lung cells.

F1000Research

Roberts JK, Moore CD, Romero EG, Ward RM, Yost GS, Reilly CA.
PMID: 24555085
F1000Res. 2013 Aug 13;2:173. doi: 10.12688/f1000research.2-173.v1. eCollection 2013.

Inhaled glucocorticoids are the first-line treatment for patients with persistent asthma.  However, approximately thirty percent of patients exhibit glucocorticoid insensitivity, which may involve excess metabolic clearance of the glucocorticoids by CYP3A enzymes in the lung.  CYP3A4, 3A5, and 3A7...

Cite
Roberts JK, Moore CD, Romero EG, et al. Regulation of CYP3A genes by glucocorticoids in human lung cells. F1000Res. 2013;2:173doi: 10.12688/f1000research.2-173.v1.
Roberts, J. K., Moore, C. D., Romero, E. G., Ward, R. M., Yost, G. S., & Reilly, C. A. (2013). Regulation of CYP3A genes by glucocorticoids in human lung cells. F1000Research, 2173. https://doi.org/10.12688/f1000research.2-173.v1
Roberts, Jessica K, et al. "Regulation of CYP3A genes by glucocorticoids in human lung cells." F1000Research vol. 2 (2013): 173. doi: https://doi.org/10.12688/f1000research.2-173.v1
Roberts JK, Moore CD, Romero EG, Ward RM, Yost GS, Reilly CA. Regulation of CYP3A genes by glucocorticoids in human lung cells. F1000Res. 2013 Aug 13;2:173. doi: 10.12688/f1000research.2-173.v1. eCollection 2013. PMID: 24555085; PMCID: PMC3869485.1.
Copy Download .nbib Format: NLM
X-Rays in the evaluation of adenoid hypertrophy: It's role in the endoscopic era.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India

Kurien M, Lepcha A, Mathew J, Ali A, Jeyaseelan L.
PMID: 23120124
Indian J Otolaryngol Head Neck Surg. 2005 Jan;57(1):45-7. doi: 10.1007/BF02907627.

OBJECTIVES: To evaluate the reliability of X-rays in the diagnosis of adenoid hypertrophy and to validate this with flexible nasopharyngoscopy which is the existing gold standard.METHOD: Lateral radiograph of the neck and a flexible nasopharyngeal endoscopy was done to...

Cite
Kurien M, Lepcha A, Mathew J, et al. X-Rays in the evaluation of adenoid hypertrophy: It's role in the endoscopic era. Indian J Otolaryngol Head Neck Surg. 2005;57(1):45-7doi: 10.1007/BF02907627.
Kurien, M., Lepcha, A., Mathew, J., Ali, A., & Jeyaseelan, L. (2005). X-Rays in the evaluation of adenoid hypertrophy: It's role in the endoscopic era. Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India, 57(1), 45-7. https://doi.org/10.1007/BF02907627
Kurien, Mary, et al. "X-Rays in the evaluation of adenoid hypertrophy: It's role in the endoscopic era." Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India vol. 57,1 (2005): 45-7. doi: https://doi.org/10.1007/BF02907627
Kurien M, Lepcha A, Mathew J, Ali A, Jeyaseelan L. X-Rays in the evaluation of adenoid hypertrophy: It's role in the endoscopic era. Indian J Otolaryngol Head Neck Surg. 2005 Jan;57(1):45-7. doi: 10.1007/BF02907627. PMID: 23120124; PMCID: PMC3451545.
Copy Download .nbib Format: NLM
Patient perspectives in the management of asthma: improving patient outcomes through critical selection of treatment options.

Patient preference and adherence

Scichilone N, Contino A, Figlioli GB, Paglino G, Bellia V.
PMID: 20165595
Patient Prefer Adherence. 2010 Feb 04;4:17-23. doi: 10.2147/ppa.s5627.

Asthma is a chronic inflammatory disorder of the airways that requires long-term treatment, the goal of which is to control clinical symptoms for extended periods with the least possible amount of drugs. International guidelines recommend the addition of an...

Cite
Scichilone N, Contino A, Figlioli GB, et al. Patient perspectives in the management of asthma: improving patient outcomes through critical selection of treatment options. Patient Prefer Adherence. 2010;4:17-23doi: 10.2147/ppa.s5627.
Scichilone, N., Contino, A., Figlioli, G. B., Paglino, G., & Bellia, V. (2010). Patient perspectives in the management of asthma: improving patient outcomes through critical selection of treatment options. Patient preference and adherence, 417-23. https://doi.org/10.2147/ppa.s5627
Scichilone, Nicola, et al. "Patient perspectives in the management of asthma: improving patient outcomes through critical selection of treatment options." Patient preference and adherence vol. 4 (2010): 17-23. doi: https://doi.org/10.2147/ppa.s5627
Scichilone N, Contino A, Figlioli GB, Paglino G, Bellia V. Patient perspectives in the management of asthma: improving patient outcomes through critical selection of treatment options. Patient Prefer Adherence. 2010 Feb 04;4:17-23. doi: 10.2147/ppa.s5627. PMID: 20165595; PMCID: PMC2819900.
Copy Download .nbib Format: NLM
Mometasone furoate in the management of asthma: a review.

Therapeutics and clinical risk management

Tan RA, Corren J.
PMID: 19337427
Ther Clin Risk Manag. 2008 Dec;4(6):1201-8. doi: 10.2147/tcrm.s3261.

Inhaled corticosteroids (ICS) have proven to be the most effective and essential therapy for the treatment of bronchial asthma. The 2007 National Asthma Education and Prevention Program guidelines recommend ICS as preferred therapy for patients with mild to severe...

Cite
Tan RA, Corren J. Mometasone furoate in the management of asthma: a review. Ther Clin Risk Manag. 2008;4(6):1201-8doi: 10.2147/tcrm.s3261.
Tan, R. A., & Corren, J. (2008). Mometasone furoate in the management of asthma: a review. Therapeutics and clinical risk management, 4(6), 1201-8. https://doi.org/10.2147/tcrm.s3261
Tan, Ricardo A, and Corren, Jonathan. "Mometasone furoate in the management of asthma: a review." Therapeutics and clinical risk management vol. 4,6 (2008): 1201-8. doi: https://doi.org/10.2147/tcrm.s3261
Tan RA, Corren J. Mometasone furoate in the management of asthma: a review. Ther Clin Risk Manag. 2008 Dec;4(6):1201-8. doi: 10.2147/tcrm.s3261. PMID: 19337427; PMCID: PMC2643101.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 145 entries